Canada: Pharma In Brief - New Decisions Relating To Pharmaceutical Pricing Information Under Access To Information Law Are Released


Continuing a line of cases dealing with access to information surrounding dealings between government and pharmaceutical manufacturers, in two decisions released on November 6, 2013, the Ontario Information and Privacy Commissioner upheld certain governmental exemptions but released other information relating to contracts and other information held by the Ontario Ministry of Health and Long-Term Care.

Decision PO-3275

This case involved information contained in a number of records relating to volume discount payments received by the ministry from a number of drug manufacturers. The ministry had withheld portions of the information on the basis of third party information (section 17) and the government's own exemption as to economic interests (section 18). The records uncovered included a chart of estimated savings as a result of Listing/Pricing Agreements, information indicating the aggregate amount of savings to the government over 2007/2008, information as to the overall weighted average percentage of savings per drug product, and finally, two separate agreements between manufacturers and the ministry. The government and third parties claimed various exemptions and the requester and certain manufacturers appealed to the Commissioner.

In considering the government's claimed exemptions, the Commissioner upheld certain of them but denied others. In particular, in respect of information in the agreements that would disclose the actual amount of guaranteed savings/payments to the ministry and the process of how the figure is calculated, the Commissioner found that disclosure of the information could reasonably be expected to both prejudice the ministry's economic interests and be injurious to the Ontario government's financial interests.

However, in respect of the aggregate or summary information representing the ministry's savings overall for a particular period, the Commissioner found that the ministry had not provided sufficiently detailed and convincing evidence that disclosure of the information could reasonably be expected to result in the harms set out in section 18. The information related to a number of third parties. The Commissioner held there is no way to extrapolate the individual portion paid by a particular affected party. The Commissioner also found that the overall aggregate information does not qualify as third party information under section 17 of the Act. Notably, however, the Commissioner did find that the overall weighted average volume discount was subject to the government's claimed exemption, and could result in harm as it could affect the ministry's ability to negotiate favorable volume discount percentages in current and future negotiations. In the result, the Commissioner found the information to be exempt from release.

In respect of the two contracts between pharmaceutical companies and the government, the Commissioner found the pricing information to be exempt from release. However, in respect of the remaining portions of the two contracts at issue, the Commissioner found that the third party exemptions claimed under section 17(1) had no application. The three part test must be satisfied. While the information at issue (other than the pricing terms) was commercial or financial information, it was not "supplied" but rather was negotiated as between the parties. The remaining information in the agreements (other than the pricing/savings terms) was therefore ordered disclosed.

Decision PO-3276

This case involved an appeal of the government's decision to release certain information contained in a 4-page Letter of Intent from the Ministry of Health and Long-Term Care to the appellant pharmaceutical manufacturer, and a 2-page letter from the appellant to the ministry.

The ministry did not claim any exemptions in respect of the two records at issue, despite the fact that they did contain pricing information. While the adjudicator notes that, "The contents of a contract involving an institution and a third party will not normally qualify as having been "supplied" for the purpose of section 17(1). The provisions of a contract, in general, have been treated as mutually generated, rather than "supplied" by the third party, even where the contract is preceded by little or no negotiation or where the final agreement reflects information that originated from a single party." Nonetheless, the adjudicator held, "Based on my review of the records, I find that some sections of the letter of intent includes pricing information which, if disclosed, could permit the requester to accurately infer the appellant's baseline pricing. On this basis, I find that the portion of the letter of intent dealing with the pricing and payment information was supplied to the ministry for the purposes of section 17(1). I further find that this information would have been supplied with a reasonable expectation of confidentiality as section 11 of the record explicitly sets out the confidential terms of the agreement." The remainder of the contents of the Letter of Intent however were not found to have been supplied.

In respect of the two-page letter, the adjudicator found that it contained information that was "supplied" by the appellant to the ministry; it refers to a discussion between the appellant and the ministry and a possible agreement arising from that discussion. It was also found to contain commercial information supplied by the appellant, and with an implicit expectation of confidentiality.

Interestingly, while release of the pricing information was found to be likely to cause harm, the appellant did not provide "detailed and convincing evidence" of harm in respect of any information, according to the adjudicator. The adjudicator found that, "The failure of a party resisting disclosure to provide detailed and convincing evidence will not necessarily defeat the claim for exemption where harm can be inferred from other circumstances. However, only in exceptional circumstances would such a determination be made on the basis of anything other than the records at issue and the evidence provided by a party in discharging its onus."

In the result, the pricing information contained in the Letter of Intent was exempt from release, but all other portions of the Letter of Intent, and the entirety of the two-page letter, were ordered disclosed.


The two recent cases follow the earlier line of Ontario cases (see our Pharma in Brief report dated October 2, 2013 under which requesters have been denied access to pricing and financial information that is identifiable to specific manufacturers, but access has been granted to certain other types of information. These cases relate only to Ontario. To the extent that other provinces may have agreements with pharmaceutical manufacturers, the confidentiality of information will be determined under each province's legislation.

Link to decisions:



Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions